Phio Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 14, 2024 | Press Releases

Marlborough, Massachusetts–(Newsfile Corp. – August 14, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more...

Phio Pharmaceuticals Announces Exploratory Collaboration with a Luxury Skin Care Company for Phio’s Patented INTASYL Compound

Aug 6, 2024 | Press Releases

Phio’s INTASYL compound targets aging skin disordersMarlborough, Massachusetts–(Newsfile Corp. – August 6, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene...

Phio Pharmaceuticals Announces New Chief Financial Officer

Aug 1, 2024 | Press Releases

Marlborough, Massachusetts–(Newsfile Corp. – August 1, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more...

Phio Pharmaceuticals Announces Exercise of Warrants for $3.1 Million Gross Proceeds

Jul 12, 2024 | Press Releases

Marlborough, Massachusetts–(Newsfile Corp. – July 12, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) (the “Company”), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to...

Phio Pharmaceuticals Announces Addition of Clinical Trial Site for its Phase 1b study of PH-762

Jul 8, 2024 | Press Releases

Five sites across the U.S. are now participating in the Phase 1b study Marlborough, Massachusetts–(Newsfile Corp. – July 8, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL®...